INflammatory MediatorS in the PathophysIology of Diabetic REtinopathy Study
Status:
Recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
The central hypothesis is that inflammation mediators are biomarkers of both systemic
diabetes and Diabetic Retinopathy (DR) progression in the aqueous and that sustained topical
ketorolac application reduces/suppresses those inflammatory mediators thereby reducing the
progression of Diabetic Retinopathy.